

References

- **Andersen HR** : Preliminary results of the DANAMI-2 trial. American College of Cardiology 51st Annual Scientific Session. *March 2002, Atlanta, Ga .*

- Antman E.M ,Louwerenburg H., Baars H. et al.**: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction : results of the ENTIRE / TIMI-23 Trial. *Circulation 2002; 105: 1642-1649.*

- Antman E.M.**: The search for replacements for unfractionated heparin. *Circulation 2001 ; 103:2310-2314.*

- Antman E.M. , Guigliano R.P. and Gibson CM. et al.** : Abciximab facilitates the rate and extent of thrombolysis: results of the TIMI-14 Trial. *Circulation 1999;99:2720-2732.*

- ASSENT -3 Investigators**: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin. *Lancet 2001; 358:605-613.*

- ASSENT Investigators** : Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT 2 double-blind randomised Trial. *Lancet 1999 ;354:716-722.*

-Aversano T, Aversano LT, passamani E, et al.: Thrombolytic therapy vs primary percutaneous intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. (*JAMA* 2002;287: 1943-51).

-Baird S , Menown B , McBride S. et al.: Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. *Eur Heart J* 2002; 23:627-632.

-Belenkie I, Knudtson ML, Roth DL , et al: Relation between flow grade after thrombolytic therapy and the effect of angioplasty on LV function: *Am Heart J* 1991;121:407-16.

-Becker RC and Pechet L: Fibrinolytics, anticoagulants, and platelet antagonists in clinical practice. In: *Becker RC and Alpert JS (eds.): Cardiovascular medicine: Practice and management. 1st ed., London, Arnold 2001; 361-368.*

-Berger P, Bell M, Holmes D, Gersh B, Gibbons R et al. : Time to perfusion with direct coronary myocardial infarction. *Am J Cardiol* 1994; 73:321-36.

-Bode c, Smalling R. W., Berg G. et al.: .RAPID II Investigator. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase and front-loaded accelerated alteplase in patients with acute myocardial infarction. *Circulation* 1996; 94:891-898.

-Boersma E, Mercado N, Poldermans D, et al.: Acute myocardial

infarction : *Lancet* 2003;361 :847-58.

-Bolli R, Triana JF, Jcroudi MO.: Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular stunning. *Circ Res* 1990;67:332-43.

-Boucek R.J.,Murphy W.P: Segmental perfusion of the coronary arteries with fibrinolysis in man following a myocardial infarction. *Am J Cardiol* 1960; 6:525-533.

- Braunwald MD ScD FRCP ,Douglas P Ziper MD MACC, Peter Libby,MD, Robbert O.Bonow,MD : taxet book of cardiovascular medicine, 7th edition, by Elsevier Inc. 2005,05:0-8089-2334-X.

-Braunwald E, Kim CB: Late establishment of patency of the infarct-related artery. /n *Julian D, Braunwald E (eds): AClite Myocardial infarction. London, WE Saunders, 1994; 147-/62.*

-Braunwald E, Pfeffer MA: Ventricular enlargement and remodeling following acute myocardial infarction: Mechanisms and management. *Am J Cardiol* 1991 ; 68: 1 D-6D.

-Braunwald E.:Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? *Circulation* 1989; 79(2): 441444.

-Brener S.J. , Zeymer U. ,Adgey A.A. et al.: Eptifibatide and lowdose tissue plasminogen activator in acute myocardial infarction: the integrelin and low-dose thrombolysis in acute myocardial infarction

(INTOAMI) trial. *J Am Coll Cardiol* 2002; 39:377-386.

-Brenner S.J. , Barr L.A, Burehenal J.KB. et al.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. *Circulation* 1998; 98: 734-741.

-Brodie BR, Stone GW, Morice MC, et al: Stent Primary Angioplasty in Myocardial Infarction Study Group. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). *Am J Cardio/* .2001;88(10): 1085-1090.

-Brodie BR, Stuckey TD, Kissling G, et al.: Importance of time to reperfusion for 30 day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. *J Am Coll Cardio/* 1998; 32: 1312-9.

-Brodie BR, Stuckey TD, Kissling G, et al : Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction. *J Am Coll Cardio/* 1996; 28:319-325.

-Brodie BR.: Primary angioplasty in a community hospital in the USA: Insights into the advantages and limitations. *Br Heart J* 1995; 73:411-412.

-Califf RM.: Combination therapy for acute myocardial infarction : fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. *Am Heart J*

2000; 139:833-37.

-Califf RM.: The rational for thrombolytic therapy. *Eur Heart J* 1996; 17 (Suppl E):2-8.

-Cannon CP. , Fuster V: Thrombogenesis, antithrombotic and thrombolytic therapy. In: *Hurst's, Fuster V, Alexander RW and O'Rourke RA (eds.): 10th ed., New York, McGraw-Hill Co. 2001; 1413.*

-Cannon CP. , Gibson C.M. ,Lambrew CT. et al: Relationship .. of symptoms -onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA* 2000,' 283:2941-7.

-Cannon C.P., Gibson C.M. ,McCabe C.H. et al.: TNK-Tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI-10B Trial. *Circulation* 1998; 98:2805-2814.

-Chazov E.I. , Mateeva L.S. and Mazaev A. V. et al: Intracoronary administration of fibrinolysis in acute myocardial infarction. *Ter Arkh* 1976; 48:8-19.

-Chesebro J.H. , Knatterud G. and Roberts R. et al.: Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and streptokinase. *Circulation* 1987; 76:142-54.

-Coccolini S, Berti G ,Maresta A.: Clinical importance of myocardial salvage :Relationship with 'choice of reperfusion strategies .*International*

journal of cardiology 1999;68(1):S79-S83.

-Collen D., Topol E.J, Tiefenbrunn A.J. et al: Coronary thrombolysis with recombinant human tissue-type plasminogen activator. A prospective, randomized, placebo-controlled trial. *Circulation* 1984; 70:1012-1017.

-Collen D. , Stassen JM, Verstraete M.: Thrombolysis with human extrinsic tissue-type plasminogen activator in rabbits with experimental jugular vein thrombosis: effect of molecular form and dose of activator ,age of the thrombus ,and route of administration. *J Clin INVEST.* 1983; 71:368-376.

-Coller BS.: Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interaction. *Thromb Haemost* 1999;82:326-36.

-Coller BS.: GP IIb/IIIa antagonists: pathogenesis and therapeutic insights from studies of c7E3 Fab. *Thromb Haemost* 1997;78:73035

-Coller BS.: Platelets and thrombolytic therapy .*N Engl J Med* 1990;322:33-42

-Dalby,bouzamondo,Lechat & Montalescot.: Transfer for primary PCI versus immediate thrombolysis in acute myocardial infarction :Meta-analysis.(2003 Oct 14, *I 08*(15): 1809-14)

-Davies CH, Ormerod OJ: Failed coronary thrombolysis, *Lancet*1998; 35/:1/91-1196

-Davies MJ, Treasure T , Richardson PD.:The pathogenesis of spontaneous arterial *dissection*.*Heart* 1996;75:434-435.

-De Boer MJ. The role of PTCA in AMI.*Z.Cardiology* 1994;*Heft* 15/16,338.

- De Lemos J. , Antman E, Gibson M. et al.: Abciximab .improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI-14 trial. Division of Cardiology, University of North Carolina, UNC Heart Center, Chapel Hill, NC, USA. mohman@med.unc.edu.; 101:239-243.
2005).

-De Lemos J.A. , Antman E.M. , McCabe C.H. et at: ST-segment resolution and infarct related artery patency and flow after thrombolytic therapy. *Am J Cardiol* 2000; 85:299-304.

-Every NR ,Parsons LS, Hlatky M,Martin JS ,Weaver WD. Acomparision of thrombolytic theraby with primary PCI for AMI. *N Engl J Med* 1996; 335:1253-60.

-Falk E, Shah PK, Fuster V.: Coronary plaque disruption. *Circulation* 1995;92:65T-671.

-Falk E.,Anderson HR: Pathology of atherosclerotic plaque:Stable,unstable and infarctional In International cardiovascular medicine: Principle and practice: Roubin GS,Califf R, O'Neil W et al New Y ork:Churchill Livingstone 1994:57-68.

-Fibrinolytic Therapy Trialists (FTT) Collaborative Group:

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. *Lancet* 1994; 343:311-322.

-Fletcher A.P. , Alkjaersig N. and Smyrniotis F. et al.: The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. *Trans Assoc Am Phys* 1958; 71:287-296.

-Forrester JS, Wyatt III, Daluz PL, et al: Functional significance of regional ischemic contraction abnormalities. *Circulation* 1976 ;54:64.

-Franzosi M.G. , Santoro E. ,De Vita C. et al.: Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the GISSI-I study. *Circulation* 1998; 98:2659-2665.

-Garcia E, Elizaga J, Perez-Castellano N, et al.: Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. *J Am Coll Cardiol* 1999; 33:605-611.

-Gibbons RJ, Holmes DR, Reeder GS. et al: Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. *N Engl J Med* 1993;328:685-691.

-Gibson CM, Cannon CP, Pinna RN, Breall LA, et al: Angiographic predictor of reocclusion after thrombolysis. *J Am Coll Cardiol* 1995;25:582-589.

-Goldman L, Cost and quality of life: Thrombolysis and primary angioplasty. *J Am Coll Cardiol* 1995 ;25 (Supplement):38S-41S.

-Gresh B.J. ,Anderson J.L:Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm-paradoxical or predictable. *Circulation*1993 .. 88:296-306.

-Grines CL, Cox DA, Stone GW et al.: Coronary angioplasty with or without stent implantation for acute myocardial infarction. *N Engl J Med* 1999;341:1949-1956.

-Grines CL, Brown KF, Marco J, et al.: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1993; 328:673-679.

-GUSTO-V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. *Lancet* 2001,357:1905-1914.

-GUSTO-III Angioplasty Substudy Investigators: A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. *N Engl J Med* 1997; 336:1621-

1628.

-GUSTO-III Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. *N Engl J Med* 1997;337:11 18-1123.

- GUSTO-IIb Investigators :A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996; 335:775-782.

-GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993; 329:673-682.

-Halkin A, Stone GW, Grines CL, Cox DA, Stuckey TD, Garcia E, Guagliumi G, Mehran R, Rutherford BD, Griffin JJ, Na Y, Tcheng JE, Turco M : Outcomes of Patients Consented But Not Randomized in a Trial of Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (The CADILLAC Registry). 2005 Dec 15;96(12):1649-55. Epub

-Hamm CW, Bertrand :M, Braunwald E.: Acute coronary syndrome without ST elevation: implementation of new guidelines . *Lancet* 2001;358:1533-38.

-Hands ME, Rutherford JD, Muller, Davies, Stone PH, et al : The in-hospital MI .The MILIS Study Group. *J Am Coll Cardiol* 1989; 14:40-6.

-Harvey D, White, Cross D, Elliot J, Norris R, Yee T:Long term

prognostic importance of patency of the IRA after thrombolysis for AMI; *Circulation* 1994;89:61-67.

-Hasdai D, Behr S, Wallentin L et al.: for the Euro Heart Survey of the Acute Coronary Syndromes (Euro Heart Survey ACS). A prospective survey of the characteristics ,treatments and outcome of patients with Acute Coronary Syndromes in Europe and Mediterranean basin. *Euro Heart J* 2002;23: 1 190-201.

-Hausleiter J, Kastrati A, Mehilli J et al.: Impact of myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from STOP AMI 1 and 2 trials): stent versus thrombolysis for occluded coronary -arteries in patients with acute myocardial infarction. *Am J Cardiol.*2003;91 (3):341-343.

-Heintzen MP, Michel CJ, Strauer BE. Thrombolysis beim akuten myokardinfarkt. *Interhist* 1996; 37:585-96.

-Hermann H.C. , Moliterno D.J. and Ohman E.M. et al.: Early percutaneous intervention strategies for patency enhancement in the emergency department: GUSTO-IV. *J Am Coll Cardiol* 2000; 36: 1486-1489.

-Hochman JS, Sleeper LA, Webb JG. et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. *N Engl J Med* 1999: 341:625-634.

-Holmes DR J r, White HD, Pieper KS, et al.: Effect of age on outcome with primary angioplasty versus thrombolysis, *J Am Coll*

*Cardiol*1999; 33:412-419.

-Holmes D.R. Jr , Califf R.M. and Topol E.J.: Lessons we have learned from the GUSTO trial. *J Am Coll Cardiol* 1995;25: (suppl) 10S.

-Huber K.: Plasminogen activator inhibitor type-1 (part two):role for failure of thrombolytic therapy.PAI-1 resistance as a potential benefit for new fibrinolytic agents .*J Thromb Thrombolysis* 2001;11:195-202.

-Huikuri HV, Castellanos A, Myerburg RJ: Sudden death due to cardiac arrhythmias. *N Engl J Med* 2001 ;345: 1473-82.

-Ijaz A. Khan and Ramesh M. Gowda: Clinical perspectives and therapeutics of thrombolysis. *Mosby. Inc.* 2003; 42(11): 1886-1889.

-Ishihara M, -Sato H, Tateishi H et al.:Time course of impaired coronary flow reserve after reperfusion in patients with acute myocardial infarction. *Br Heart J* 2005;78:1103-1108

-Ishihara M, Sato H, Tateishi H et al.: Impaired coronary flow reserve immediately after coronary angioplasty in patients with acute myocardial infarction .*Br Heart J* 1996;69:288-292.

-ISIS 2 (Second International Study of Infarct Survival) Collaborative Group.: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 171,817 cases of suspected acute myocardial infarction. *Lancet* 1988,;2:349-60.

- **Jun Dong, MD; Gjin Ndrepepa, MD; Claus Schmitt, MD:**Early resolution of ST segment elevation correlates with myocardial salvage assessed by Tc-99m Sestamibi Scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. *Circulation*. 2002; 105.: 2946-2949.

- King FYJ, Chu TSJ, Goh ASW et al.:**Tc 99m sestamibi for assessment of myocardial salvage following reperfusion therapy in acute myocardial infarction .*Ann Acad Med Singapore* 2000; 29: 224-30

- **Kleiman N.S. , Ohman E.M. and Califf R. et al.:** Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the T AMI -8 pilot study. *JAm Coll Cardiol* 1993; 22:381-389.

- Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Mitsuba N, Hata T, Nakama Y, Kisaka T, Kijima Y.:** Department of Cardiology, Hiroshima City Hospital, Hiroshima 730-8518, Japan. skurisu@nifty.com 2005).

- Lamfers EJ, Hooghoudt TE, Uppelschoten A, et al.:** Effect of prehospital thrombolysis on aborting acute myocardial infarction. *Am J Cardio!*1999;84:928-38 .

- Lee L ,Erbel R, Brown TM, Laufer N, et al :** Initial and long term survival of angioplasty with AMI.*Am J Coll Cardiol* 1991;17:599-603.

- Lefer AM, Campbell B, Scalia R, Lefer DJ:**Synergism between

platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion:role of selectins.*Circulation* 1998;98: 1322-28

-Lefkowitz J. , Ivanhoe RJ. and Califf RM. et al.: Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six month outcomes after percutaneous trans luminal coronary angioplasty for acute myocardial infarction. *Am JCardiol* 1996; 77:1045-1051.

-Libby P: Molecular basis of the acute coronary syndromes. *Circulation* 1995;91:2844-2E50.

-Lincoff AM, Topol EJ, Califf RM, Lee KL, et al.:Significance of thrombolysis and angioplasty with MI grade 2 flow. *Am J Cardiol* 1995;65:81-7.

-Lorasa C Infusino F Sgueglia GA Aurigemma C Sestito A,et al: Effect of primary percutaneous coronary intervention versus thrombolysis on ventricular arrhythmias and heart rate variability in acute myocardial infarction. *2005 Aug;6(8):629-33.*

-Maggioni A.P. , Franzosi M.G. ,Santoro E. et al.: The risk of stroke in patients with acute myocardial infarction after thrombolytic and anti thrombotic treatment. *New Engl J* 1992:Med 327:1-6.

-Majerus P. W, Tollefsen D.M.: Anticoagulant, thrombolytic, and antiplatelet drugs. *Goodman & Gilman's the pharmacological basis of therapeutics (10th ed)* 2001 ; 1519-1538New York: McGraw-Hill

-Mark D.B. , Htlatky M.A. ,Califf R.M. et al.: Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator RS compared with streptokinase for acute myocardial infarction. *N Engl ,Med* 1995; 332:1418-1424.

-McKay RG.: Evolving strategies in the treatment of acute myocardial infarction in the community hospital setting. *Excerpta Medica /nc* 2003; 42:4: 642-645.

-Michel ,Schroder R, et al. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates. *Circulation.*(2003 , 91: 476-85).

-Montalescot G. , Barragan P, Wittenberg O. et al.: Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. *N Engl J Med* 2001; 344: 1895-1903.

-Morrison L.J. , Verbeek P.R, McDonald A.C. et al.: Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. *JAMA* 2000;283:2686-2692.

-Morris KG ,Palmeri ST, Califf RM, Mckinnis RA, et al.: Value of radionuclide angiography for predicting specific events after AMI: *Am J Cardiol* 1985;55:318-24.

-Moscucci M, Bates ER. Treatment of acute myocardial infarction: Cardiogenic shock. *Cardiol Clin* 1995; 13(3):391-406.

-Nallamothu BK, Antman EM, et al. Primary PCI versus fibrinolytic treatment in acute myocardial infarction :Does the choice af fibrinolytic agents impact on the importance of time-to-treatment. *Am J Cardial* ;2004 Sep , 5,94(6):772-4).

- Neuhaus K.L. , Molhoek C.P, Zeymer U. et al.: Recombinant hirudin for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. *JAm'Coll Cardiol*1999; 34:966-973.

-Newby LK, Rutsch WR, Califf RM et al.:GUSTO-I Investigator.Time from onset to treatment and outcomes after thrombolytic therapy. *JAm Coil Cardiol*1996; 27:1646-55.

-Nunn CM, O'Neill WW, Rothbaum D, et al.: Long-term outcome after primary angioplasty: Report from the Primary Angioplasty in . Myocardial Infarction (PAMI-I) trial. *J Am Coil Cardiol* 1999; 33:640-646.

-O'Kieef JH, Rutherford BD, McConahay DR, Ligon RW, et al.;Ealy and late results of angioplasty without antecedent thrombolytic theraby for AMI. *Am J Cardiol*;1990;22:16-23.

-O'Neill W ,Brodie BR: Mechanical. interventions in acute myocardial infarction. In: *Hurst's, Fuster V, Alexander RW and O'Rourke RA (eds.): The Heart. 10th ed, New york, McGraw-Hill Co. 2001; p. 1473, 1474, 1477, 1479-1482.*

-O'Neill WW, Brodie BR, Ivanhoe R, et al.: Primary coronary angioplasty for acute myocardial infarction (The Primary Angioplasty Registry). *Am J CardioI*1994;' 73:627-634.

-Ohman, EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW:Intravenous Thrombolysis in Acute Myocardial Infarction *Chest* 2001;119:2538-2775 .

-Ohman EM , Kleiman NS, Gadoch G et al.: Combined accelerated tissue plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. *Circulation* 1997; 95:846-854.

-Pfeffer MA: Left ventricular remodeling after acute myocardial infarction. *Ann Rev Med* 1995; 46:455-466.

-Pfeffer MA, Lamas GA, Vaughan DE, et al: Effect of captor;ril on progressive ventricular dilatation after anterior myocardial infarction. *N Engl J Med* 1988; 319:80-86

-Reitsma JR, Dalstra JA, BonseI GJ: Cardiovascular disease in the Netherlands,1975 to 1995:decline in mortality, but increase in numbers of patient with chronic conditions. *Heart* 1999;82:52-56.

-Rentrop P. , Blanke H. ,Karsch K.R et al.: Selective intracoronary thrombo~ysis in acute myocardial infarction and unstable angina pectoris. *Circulation* 1981; 63:307-317.

-Ribichini F, Steffenino G, Dellavalle A, et al.: Comparison of thrombolytic therapy and primary coronary angioplasty for inferior MI with precordial ST- Segment depression. *J Am Cardiol* 32:1687-1694.1998.

-Richard E. Waters, Kenneth W. Mahaffey, Christopher B. Granger, Matthew T. Roe:Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. *American College of Cardiology Foundation* 2003; 42: 11:18861889.

- Ryan TJ, Antman EM, Brooks NH, et al: 1999 update: ACC/ AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *Circulation*1999; 100: 1016-1030.

-Sane D.C. , Califf R.M, Topol E.J. et al.: Bleeding during thrombolytic therapy for acute myocardial infarction. Mechanisms and management. *Ann intern Med* 1989; /11:1010.

-Schmermund A; Lerman LO, Ritman EL, Rumberger JA: Cardiac production of angiotensin II and its pharmacologic inhibition: Effects on the coronary circulation. *Mayo Clin Proc* 1999 ;74:503-513.

-Schomig A, Ndrepaepa G, Mehilli J, et al.: Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients

with acute myocardial infarction treated with coronary artery stenting or thrombolysis. *Circulation*.2003;108(9): 1084-1088

-Schuster EH, Bulkley BH: Ischemia at a distance after acute myocardial infarction: A cause of early postinfarction angina. *Circulation* 1980; 62:509-515.

Shroder K, Wegscheider, Zeymer, et al.: Extent of ST- segment deviation in a single ECG lead 90 minute after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction.(*Lancet*, 2001 ;358: 1479-86).

-Simoons ML, Maggioni AP, Knatterud et al: Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. *Lancet* 1993;342:1523-1528.

- **SPEED Group:** Trial of abciximab ,with and without low-dose reteplase for acute myocardial infarction. *Circulation* 2000; 100:2788-2794.

-Steven B, O'Keef J, Gibson J.Incidence and importance of thrombolysis in MI grade 3 flow and after PCI for AMI. *Am J Cardiol* 1996;78:623-626.

- **Stone GW , Grines CL, Cox DA et al.:** Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction *N Engl J Med* 2002; 346:957-966.

- **Stone G. , Cox D. ,Garcia E. et al.:** Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the Primary Angioplasty in Myocardial Infarction trials. *Circulation* 2001,; 104:636-641.

- **Stone GW, Grincs CL, Rothbaum D, Kevin F, Browne, et al:** The primary angioplasty in MI (PAMI) trial. *J Am Coll C ardiol* 1997; 29:901-907.

- **Stone GW, Grincs CL, Browne KF, et al.:** Influence of acute myocardial iIfarction location on in-hospital and late outcome after primary percutaneous trans luminal coronary angioplasty versus tis.sue plasminogen activator therapy. *Am J Cardiol*1996; 78:19-25.

-**Stone GW, Grines CL, Browne KF, et al.:** Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction,AM J cardioll 1995,75:987-992.

-**Sutton MG, Sharpe N:** Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. *Circulation* 2000;101:2981-2988.

-**Taegtmeyer H:** Metabolic support of the post ischemic heart. *Lancet* 1995;345:1552-1555.

-**Topol EJ:** Acute myocardial infarction: thrombolysis. *Heart* 2000;83: 122-26.

-Tunstall-Pedoe H: Comment on the ESC/ACC redefinition of myocardial infarction by a consensus dissenter. *Eur Heart J* 2001 ;22;613: 16.

-Tunstall-Pedoe H, Kuulasmaa K , Amouyel P,et al.:Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates ,and casefatality rates in 38 populations from 21 countries in four continents. *Circulation* 1994;90:583-612.

-Vakili B. , Kaplan R, Brown D.L: Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York State. *Circulation* 2001; 104:2171 -2176 .

- Van den Merkhof Lambert F.M. , Zijlstra F, Olsson H. et al.: Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the GRAPE pilot study. *JAm Coll Cardiol* 1999; 33:528-532.

-Veen G, de Boer MJ, Zijlstra F, et al: Improvement in three-month angiographic outcome suggested after primary angioplasty for acute myocardial infarction (Zwolle trial) compared with successful thrombolysis (APRICOT trial). *Am J Cardiol* 1999; 84:763-767.

-Verstraete M: Third-generation thrombolytic agents. *Am J Cardiol* 2000 ; 109:52-58.

-Vivekananthan DP, Lauer MA.: Acute Myocardial Infarction. *In Eric*

J. Topol and Brian P. Griffin (eds): Manual of cardiovascular medicine: 2nd ed. 2004; I :3-27.

- **Weaver W.O. , Simes R.J. ,Betriu A. et al.:** Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. *JAMA* 1997; 278:2093-2098.

- **Weaver W.D: Time to thrombolytic treatment:** Factors affecting the delay and their" influence on outcome. *J Am Coll Cardiol* 1995 258:35-95.

-**Weaver W.D, Cerqueira M. and Hallstrom A.P. et al:** Prehospital - initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. *JAMA* 1993; 270:1211-1216.

-**Weisman HF, Bush DE, Mannisi JA, et al:** Cellular mechanisms of myocardial infarct expansion. *Circulation* 1988 ; 78:186-201 .

-**Weisman HF, Healy B:** Myocardial infarct expansion, infarct extension, and reinfarction : pathophysiologic concepts. *Frog Cardiovasc Dis* 1987; 30:73-110.

-**White H.D. ,Van de., Werf F.J.J. :** Clinical cardiology: new frontiers: Thrombolysis for acute myocardial infarction. *Circulation* 1998; 97:1632-1646.

-**White H.D. , Aylward P.E. ,Frey M.J. et al. :** Randomized, double blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction.

*Circulation*1997; 96:2155-2161

-White HD, French JK, Hamer A W, et al.: Frequent re-occlusion of patent infarct-related arteries between four weeks and one year: Effects of anti-platelet therapy. *J Am Coll Cardiol* 1995; 25:2182-23.

-White HD, Norris RM, Brown MA, et al: Left ventricular endsystolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation* 1987;76:44-51.

-William J, Rogers, Dean L, Moore K, Wool K, Burgard L and Bradley E. Comparison of primary PCI versus thrombolysis for AMI. *Am J Cardiol* 1994;74:111-8.

-Wilson S.H. , Beli M.R, Rihal C.S. et al.: Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction. *Am Heart J* 2001; 141:704-710.

-Wu AH, Apple FS, Gibler WH, Jesse RL. et al.:National Academy of Clinical Biochemistry Standards of Laboratory Practice : recommendations for the use of cardiac markers in coronary artery disease. *Clin Chem*1999;45:1104-21.

-Zahn R, Schuster S, Gottwik M, et al.: Comparison of primary angioplasty with. conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy (abstract). *Circulation* 1998; 98(17, suppl1):/-558.

- Zijlstra F, Hoorntje JCA, de Boer M-J, et al.: Long-term benefit of

primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999; 341: 1413-1419.

-Zijlstra F, Beukema WP, van't Hof A WJ. et al.: Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. *J Am Coll Cardiol* 1997; 29:908-912.

-Zijlstra F, Jan de Boer M, Hoorntje JCA. et al.: A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med* 1993; 328:680-684.